| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 具有降低血中尿酸值作用的乳酸菌 | CN200780102278.8 | 2007-11-29 | CN101932697A | 2010-12-29 | 坪井洋; 金子纪子; 佐藤秋莱; 土屋义信 |
| 本发明涉及一种具有降低血中尿酸值作用的乳酸菌。本发明在嘌呤体存在下培养各种乳酸菌，测定该嘌呤体的消耗量以及该嘌呤体分解物的产生量，挑选嘌呤体分解能力显著的多种乳酸菌。将通过上述挑选被判断为嘌呤体分解能力高的乳酸菌经口给予用含有嘌呤体的饲料喂养的大鼠，测定该大鼠的一般状况和血清尿酸值，研究给予乳酸菌对血清尿酸值的影响。结果发现了能够显著抑制血清尿酸值上升的乳酸菌：格氏乳杆菌OLL2959和口乳杆菌OLL2779。 | ||||||
| 2 | 具有降低血中尿酸值作用的乳酸菌 | CN200780102278.8 | 2007-11-29 | CN101932697B | 2012-08-29 | 坪井洋; 金子纪子; 佐藤秋莱; 土屋义信 |
| 本发明涉及一种具有降低血中尿酸值作用的乳酸菌。本发明在嘌呤体存在下培养各种乳酸菌，测定该嘌呤体的消耗量以及该嘌呤体分解物的产生量，挑选嘌呤体分解能力显著的多种乳酸菌。将通过上述挑选被判断为嘌呤体分解能力高的乳酸菌经口给予用含有嘌呤体的饲料喂养的大鼠，测定该大鼠的一般状况和血清尿酸值，研究给予乳酸菌对血清尿酸值的影响。结果发现了能够显著抑制血清尿酸值上升的乳酸菌：格氏乳杆菌OLL2959和口乳杆菌OLL2779。 | ||||||
| 3 | Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | US14829868 | 2015-08-19 | US09867857B2 | 2018-01-16 | Siao-Jhen Cheng; Yen-Lin Chen; Hsun-Yin Hsu; Kai-Ping Chen; Chiao-Ming Liao; Yi-Jen Yech |
| A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing Gluconacetobacter hansenii or Acetobacter pasteurianus in a medium. Also disclosed is a pharmaceutical composition and a food product that each include a metabolite of Gluconacetobacter hansenii or Acetobacter pasteurianus for reducing uric acid levels in a subject and methods for producing the pharmaceutical composition and the food product. | ||||||
| 4 | Lactic acid bacteria having action of lowering blood uric acid level | US12745007 | 2007-11-29 | US08460918B2 | 2013-06-11 | Hiroshi Tsuboi; Noriko Kaneko; Akina Satou; Yoshinobu Tsuchiya |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 5 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL | US12745007 | 2007-11-29 | US20110014168A1 | 2011-01-20 | Hirosi Tsuboi; Noriko Kaneko; Akina Satou; Yoshinobu Tsuchiya |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 6 | NOVEL ACETOBACTER AND GLUCONACETOBACTER STRAINS AND THEIR METABOLITES FOR USE IN INHIBITING XANTHINE OXIDASE | US14829868 | 2015-08-19 | US20160051598A1 | 2016-02-25 | Siao-Jhen Cheng; Yen-Lin Chen; Hsun-Yin Hsu; Kai-Ping Chen; Chiao-Ming Liao; Yi-Jen Yech |
| A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing Gluconacetobacter hansenii or Acetobacter pasteurianus in a medium. Also disclosed is a pharmaceutical composition and a food product that each include a metabolite of Gluconacetobacter hansenii or Acetobacter pasteurianus for reducing uric acid levels in a subject and methods for producing the pharmaceutical composition and the food product. | ||||||
| 7 | Lactic acid bacteria having action of lowering blood uric acid level | US13544756 | 2012-07-09 | US08541223B2 | 2013-09-24 | Hiroshi Tsuboi; Noriko Kaneko; Akina Satou; Yoshinobu Tsuchiya |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 8 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL | US13544756 | 2012-07-09 | US20120308539A1 | 2012-12-06 | Hiroshi Tsuboi; Noriko Kaneko; Akina Satou; Yoshinobu Tsuchiya |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 9 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL | EP07832808.5 | 2007-11-29 | EP2221359B1 | 2014-01-15 | TSUBOI, Hiroshi; KANEKO, Noriko; SATOU, Akina; TSUCHIYA, Yoshinobu |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were, measured, and several lactic acid bacteria showing remarkable purme-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 10 | PROCESS FOR PRODUCING CONJUGATED LINOLENIC ACID FROM LINOLENIC ACID EMPLOYING BIFIDOBACTERIUM BREVE, BIFIDOBACTERIUM BIFIDUM, OR LACTOBACILLUS ORIS STRAINS | EP13817928.8 | 2013-12-20 | EP2935600A2 | 2015-10-28 | MORENO MUÑOZ, José Antonio; RIVERO URGELL, Montserrat; CIFUENTES ORJUELA, Gloria Clemencia; MARTÍN GARCÍA, Francisco José; RODRÍGUEZ-PALMERO SEUMA, María; PUIGJANER RIBA, Joaquim; VILLAR TAJADURA, María Antonia; RODRÍGUEZ ALCALÁ, Luis Miguel; REQUENA ROLANIA, Teresa; FONTECHA ALONSO, Francisco Javier |
| Method for preparing isomers of conjugated linolenic acid (CLNA) from linolenic acid(LNA) in a medium comprising at least the fat portion contained in a milk-based productor composition, in which at least one strain of a lactic acid bacteria or a bifidobacteria selected from the species of the group consisting of Bifidobacterium breve, Bifidobacterium bifidumand Lactobacillus oris is used. The invention also includes particular strains of all these species that allow performing the method in with high yields and conversion rates, as well as food products, nutritional compositions and pharmaceutical compositions containing them which are useful as anti-obesity agents and as immunomodulator agents. | ||||||
| 11 | Lactic acid bacteria having action of lowering blood uric acid level | EP12002386.6 | 2007-11-29 | EP2476747B1 | 2014-09-03 | Tsuboi, Hiroshi; Kaneko, Noriko; Satou, Akina; Tsuchiya, Yoshinobu |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were, measured, and several lactic acid bacteria showing remarkable purme-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 12 | Process for producing conjugated linolenic acid from linolenic acid employing Bifidobacterium breve, Bifidobacterium bifidum, or Lactobacillus oris strains. | EP12199104.6 | 2012-12-21 | EP2746398A1 | 2014-06-25 | Moreno Muñoz, José Antonio; Rivero Urgell, Montserrat; Cifuentes Orjuela, Gloria Clemencia; Martín Garciá, Francisco José; Rodríguez-Palmero Seuma, María; Puigjaner Riba, Joaquim; Villar Tajadura, María Antonia; Rodríguez Alcalá, Luis Miguel; Requena Rolania, Teresa; Fontecha Alonso, Francisco Javier |
Method for preparing isomers of conjugated linolenic acid (CLNA) from linolenic acid (LNA) in a medium comprising at least the fat portion contained in a milk-based product or composition, in which at least one strain of a lactic acid bacteria or a bifidobacteria selected from the species of the group consisting of Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus oris is used. The invention also includes particular strains of all these species that allow performing the method in with high yields and conversion rates, as well as food products, nutritional compositions and pharmaceutical compositions containing them which are useful as anti-obesity agents and as immunomodulator agents.
|
||||||
| 13 | Lactic acid bacteria having action of lowering blood uric acid level | EP12002386.6 | 2007-11-29 | EP2476747A1 | 2012-07-18 | Tsuboi, Hiroshi; Kaneko, Noriko; Satou, Akina; Tsuchiya, Yoshinobu |
Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. |
||||||
| 14 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL | EP07832808 | 2007-11-29 | EP2221359A4 | 2011-11-02 | TSUBOI HIROSHI; KANEKO NORIKO; SATOU AKINA; TSUCHIYA YOSHINOBU |
| Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were, measured, and several lactic acid bacteria showing remarkable purme-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. | ||||||
| 15 | LACTIC ACID BACTERIA HAVING ACTION OF LOWERING BLOOD URIC ACID LEVEL | EP07832808.5 | 2007-11-29 | EP2221359A1 | 2010-08-25 | TSUBOI, Hiroshi; KANEKO, Noriko; SATOU, Akina; TSUCHIYA, Yoshinobu |
Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were, measured, and several lactic acid bacteria showing remarkable purme-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found. |
||||||
| 16 | 혈중 요산치 저감작용을 갖는 유산균 | KR1020107013960 | 2007-11-29 | KR101385864B1 | 2014-04-17 | 츠보이히로시; 가네코노리코; 사토우아키나; 츠치야요시노부 |
| 푸린체(purines) 존재하에서 각종 유산균을 배양하고, 그 푸린체의 소비량 및 그 푸린체 분해물의 생산량을 측정하여, 푸린체 분해능이 현저한 복수의 유산균을 선발하였다. 상기 선발에 의해 푸린체 분해능이 높다고 판단된 유산균을, 푸린체 함유 사료로 사육한 랫트에 경구투여하고, 당해 랫트의 일반상태 및 혈청 요산치를 측정하여, 유산균 투여에 따른 혈청 요산치로의 영향을 검토하였다. 그 결과, 혈청 요산치의 상승을 유의하게 억제하는 유산균:Lactobacillus gasseri OLL2959 및 Lactobacillus oris OLL2779를 발견하였다. | ||||||
| 17 | 혈중 요산치 저감작용을 갖는 유산균 | KR1020107013960 | 2007-11-29 | KR1020100103805A | 2010-09-28 | 츠보이히로시; 가네코노리코; 사토우아키나; 츠치야요시노부 |
| 푸린체(purines) 존재하에서 각종 유산균을 배양하고, 그 푸린체의 소비량 및 그 푸린체 분해물의 생산량을 측정하여, 푸린체 분해능이 현저한 복수의 유산균을 선발하였다. 상기 선발에 의해 푸린체 분해능이 높다고 판단된 유산균을, 푸린체 함유 사료로 사육한 랫트에 경구투여하고, 당해 랫트의 일반상태 및 혈청 요산치를 측정하여, 유산균 투여에 따른 혈청 요산치로의 영향을 검토하였다. 그 결과, 혈청 요산치의 상승을 유의하게 억제하는 유산균:Lactobacillus gasseri OLL2959 및 Lactobacillus oris OLL2779를 발견하였다. | ||||||
| 18 | 혈중 요산치 저감작용을 갖는 유산균 | KR1020147004136 | 2007-11-29 | KR101450511B1 | 2014-10-15 | 츠보이히로시; 가네코노리코; 사토우아키나; 츠치야요시노부 |
| 푸린체(purines) 존재하에서 각종 유산균을 배양하고, 그 푸린체의 소비량 및 그 푸린체 분해물의 생산량을 측정하여, 푸린체 분해능이 현저한 복수의 유산균을 선발하였다. 상기 선발에 의해 푸린체 분해능이 높다고 판단된 유산균을, 푸린체 함유 사료로 사육한 랫트에 경구투여하고, 당해 랫트의 일반상태 및 혈청 요산치를 측정하여, 유산균 투여에 따른 혈청 요산치로의 영향을 검토하였다. 그 결과, 혈청 요산치의 상승을 유의하게 억제하는 유산균:Lactobacillus gasseri OLL2959 및 Lactobacillus oris OLL2779를 발견하였다. | ||||||
| 19 | 혈중 요산치 저감작용을 갖는 유산균 | KR1020147004136 | 2007-11-29 | KR1020140032503A | 2014-03-14 | 츠보이히로시; 가네코노리코; 사토우아키나; 츠치야요시노부 |
| 푸린체(purines) 존재하에서 각종 유산균을 배양하고, 그 푸린체의 소비량 및 그 푸린체 분해물의 생산량을 측정하여, 푸린체 분해능이 현저한 복수의 유산균을 선발하였다. 상기 선발에 의해 푸린체 분해능이 높다고 판단된 유산균을, 푸린체 함유 사료로 사육한 랫트에 경구투여하고, 당해 랫트의 일반상태 및 혈청 요산치를 측정하여, 유산균 투여에 따른 혈청 요산치로의 영향을 검토하였다. 그 결과, 혈청 요산치의 상승을 유의하게 억제하는 유산균:Lactobacillus gasseri OLL2959 및 Lactobacillus oris OLL2779를 발견하였다. | ||||||
| 20 | PROCESS FOR PRODUCING CONJUGATED LINOLENIC ACID FROM LINOLENIC ACID EMPLOYING BIFIDOBACTERIUM BREVE, BIFIDOBACTERIUM BIFIDUM, OR LACTOBACILLUS ORIS STRAINS | PCT/EP2013077671 | 2013-12-20 | WO2014096352A3 | 2014-08-21 | MORENO MUÑOZ JOSÉ ANTONIO; RIVERO URGELL MONTSERRAT; CIFUENTES ORJUELA GLORIA CLEMENCIA; MARTÍN GARCÍA FRANCISCO JOSÉ; RODRÍGUEZ-PALMERO SEUMA MARÍA; PUIGJANER RIBA JOAQUIM; VILLAR TAJADURA MARÍA ANTONIA; RODRÍGUEZ ALCALÁ LUIS MIGUEL; REQUENA ROLANIA TERESA; FONTECHA ALONSO FRANCISCO JAVIER |
| Method for preparing isomers of conjugated linolenic acid (CLNA) from linolenic acid (LNA) in a medium comprising at least the fat portion contained in a milk-based productor composition, in which at least one strain of a lactic acid bacteria or a bifidobacteria selected from the species of the group consisting of Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus oris is used. The invention also includes particular strains of all these species that allow performing the method in with high yields and conversion rates, as well as food products, nutritional compositions and pharmaceutical compositions containing them which are useful as anti-obesity agents and as immunomodulator agents. | ||||||
QQ群二维码
意见反馈
意见反馈